Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma

Titas Banerjee, Anusha Vallurupalli

Research output: Contribution to journalArticlepeer-review


Abstract:Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B-lymphocytes, T-lymphocytes, or natural killer (NK) lymphocytes. First line therapy is well established and generally a combination of steroids and chemotherapy. Treatment of relapsed/refractory (R/R) NHL however remains a challenge with rapidly evolving new therapies. Many of these new therapies focus on manipulating the body's natural immune mechanisms to identify and eradicate tumor cells. There has been much success with using checkpoint inhibitors in Hodgkin's Lymphoma (HL). However, results have been modest in NHL, prompting further studies of immunomodulatory strategies to target NHL. In this article, we review the emerging immune and cell therapies for R/R B-NHL including checkpoint inhibitors, bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapy, and small molecule inhibitors both alone and in combination.

Original languageEnglish (US)
Article number100825
JournalCurrent problems in cancer
Issue number1
StatePublished - Feb 2022


  • Bispecific Antibodies
  • CAR-T Therapy
  • Checkpoint Inhibitors
  • Immunotherapy
  • Non-Hodgkin's Lymphoma
  • Novel Therapy
  • Small molecule inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this